Maravai LifeSciences Q3 2023 Earnings Report $5.58 -0.22 (-3.79%) (As of 05:44 PM ET) Earnings HistoryForecast Maravai LifeSciences EPS ResultsActual EPS-$0.02Consensus EPS -$0.03Beat/MissBeat by +$0.01One Year Ago EPSN/AMaravai LifeSciences Revenue ResultsActual Revenue$66.87 millionExpected Revenue$75.23 millionBeat/MissMissed by -$8.36 millionYoY Revenue GrowthN/AMaravai LifeSciences Announcement DetailsQuarterQ3 2023Date11/7/2023TimeN/AConference Call ResourcesSlide DeckPress ReleaseMRVI Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by Why I'm telling friends to avoid gold stocks (Ad)Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Maravai LifeSciences Earnings HeadlinesMaravai LifeSciences (NASDAQ:MRVI) Lowered to "Sell" Rating by The Goldman Sachs GroupDecember 8, 2024 | americanbankingnews.comCraig-Hallum Sticks to Their Buy Rating for Maravai Lifesciences Holdings (MRVI)December 6, 2024 | markets.businessinsider.comI want to send you my Cash CalendarThis Calendar reveals the EXACT dates that — if everything goes right — anyone can target cash payouts of $125, $415, and even $1,665. (With just a $1,000 starting stake!) Granted, there were smaller wins and those that did not work out and we cannot promise future returns or against losses, but these payouts don’t require any special knowledge or skills. Anyone can set them up with just three clicks in their brokerage account. And the money can be deposited in their account the very next morning after opening the trade. Again, I want to send this Cash Calendar to you completely FREE. All you have to do is join me for my free Cash Calendar training right here. You don’t want to miss this. There is a very special bonus surprise for everyone who attends. December 18, 2024 | Wealthpin Pro (Ad)Goldman Sachs Downgrades Maravai LifeSciences Holdings (MRVI)December 6, 2024 | msn.comMaravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of DirectorsDecember 5, 2024 | globenewswire.comMaravai LifeSciences: Still Struggling To Find Its FootingNovember 25, 2024 | seekingalpha.comSee More Maravai LifeSciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Maravai LifeSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Maravai LifeSciences and other key companies, straight to your email. Email Address About Maravai LifeSciencesMaravai LifeSciences (NASDAQ:MRVI), a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.View Maravai LifeSciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
